Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality

Russo, Mark W.; Sood, Asheesh; Jacobson, Ira M.; Brown Jr., Robert S.
November 2003
American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2521
Academic Journal
: ObjectivesTransjugular intrahepatic portosystemic shunt (TIPS) is frequently used to treat patients with refractory ascites, but its role is controversial. We sought to determine from the literature the efficacy, morbidity, and mortality associated with TIPS for refractory ascites.: MethodsWe searched MEDLINE and identified studies published in English from January, 1985, to March, 2003, that evaluated the effect of TIPS in patients with refractory ascites. Outcomes that were analyzed included complete resolution of ascites, reduction in ascites, mortality, encephalopathy, stenosis, and renal function. Data were analyzed on an intention to treat basis.: ResultsOf 25 studies identified, 16 were included in the analysis. The pooled estimate for complete response at 6 months was 45% and for any response (complete and partial) was 63%. Pooled 6-month mortality after TIPS was 36%. Risk factors for mortality included renal insufficiency (serum creatinine >1.5 mg/dl), hyperbilirubinemia (total bilirubin >3 mg/dl), advanced age (>60 yr), and poor response to TIPS. The pooled rate of new or worsening encephalopathy after TIPS was 32%. In most cases, encephalopathy was managed medically or by reduction in shunt size; however, refractory cases were associated with 100% mortality in most studies. Studies reporting the effect of TIPS on kidney function showed improvement in creatinine clearance and urinary sodium excretion.: ConclusionsTIPS is effective in eliminating ascites or substantially reducing ascites in cases refractory to medical therapy. Renal insufficiency, refractory encephalopathy, and hyperbilirubinemia were consistently associated with mortality after TIPS. In individuals with risk factors for mortality, alternative strategies should be recommended.


Related Articles

  • Early and Late Morbidity of Portasystemic Shunts Including Experience with Seven H-grafts. Smith III, Robert B.; Perdue Jr., Garland D. // American Journal of Gastroenterology;Oct1972, Vol. 58 Issue 4, p396 

    Experience with 67 consecutive portasystemic shunting procedures has been reviewed and the postoperative morbidity and mortality analyzed. The data indicate an acceptable hospital and follow-up mortality among better risk patients undergoing elective shunt procedures, but the results leave much...

  • Hepatic Vein Stenting for Budd-Chiari Syndrome. Witte, A. M. C.; Schultze Kool, L. J.; Veenendaal, R.; Tamers, C. B. H. W.; Van Hoek, B. // American Journal of Gastroenterology;Mar1997, Vol. 92 Issue 3, p498 

    This report describes two patients with Budd-Chiari syndrome with intractable ascites due to a tight hepatic vein stenosis while the other hepatic veins were occluded. Percutaneous transluminal angioplasty of the hepatic vein stenosis followed by insertion of expandable metallic stents reduced...

  • Spontaneous bacterial peritonitis: A severe complication of liver cirrhosis. Lata, Jan; Stiburek, OldÅ™ich; Kopacova, Marcela; Zimmerman, Michael A. // World Journal of Gastroenterology;11/28/2009, Vol. 15 Issue 44, p5505 

    This report presents a survey of current knowledge concerning one of the relatively frequent and severe complications of liver cirrhosis and associated ascites-spontaneous bacterial peritonitis. Epidemiology, aetiology, pathogenesis, clinical manifestation, diagnosis and present possibilities of...

  • Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. Sheth, Milan; Riggs, Mark; Patel, Tushar // BMC Gastroenterology;2002, Vol. 2, p2 

    Background: Alcoholic hepatitis is characterized by acute, or acute-on-chronic hepatic failure and associated with a high mortality. Specific therapies should be considered for those at high risk of mortality. The Mayo End-Stage Liver Disease (MELD) score is a marker of disease...

  • High mortality of pneumonia in cirrhotic patients with ascites. Hung, Tsung-Hsing; Tseng, Chih-Wei; Hsieh, Yu-Hsi; Tseng, Kuo-Chih; Tsai, Chih-Chun; Tsai, Chen-Chi // BMC Gastroenterology;2013, Vol. 13 Issue 1, p1 

    Background: Cirrhotic patients with ascites are prone to develop various infectious diseases. This study aimed to evaluate the occurrence and effect of major infectious diseases on the mortality of cirrhotic patients with ascites. Methods: We reviewed de-identified patient data from the National...

  • Predictors of poor outcomes in functionally dependent patients undergoing ventral hernia repair. Reynolds, Drew; Davenport, Daniel; Roth, J. // Surgical Endoscopy;Apr2013, Vol. 27 Issue 4, p1099 

    Background: Preoperative functional health status has been shown previously to affect outcomes following ventral hernia repair. The objective of this study was to identify specific factors that contribute to morbidity and mortality in functionally dependent patients who undergo elective ventral...

  • Spontaneous Umbilical Hernia Rupture. Fisher, John; Calkins, W. Graham // American Journal of Gastroenterology;Jun1978, Vol. 69 Issue 6, p689 

    Three cases of spontaneous umbilical hernia rupture in patients with alcoholic liver disease and ascites are reported. Eighteen cases have been previously reported in the literature. These 21 eases are reviewed in an attempt to determine precipitating events, prognostic factors, complications,...

  • MANAGEMENT OF "REFRACTORY" ASCITES. Shinaberger, James H.; Galambos, John T. // American Journal of Gastroenterology;May1964, Vol. 41 Issue 5, p499 

    Discusses the management and treatment of refractory ascites in cirrhotic patients. Information on the therapeutic challenges encountered by people with liver diseases; Hepatic and portal hydrodynamic factors associated with ascites formation; Description of the therapy of hepatic and...

  • Nodular Regenerative Hyperplasia: A Cause of Ascites and Hepatomegaly after Chemotherapy for Leukemia. Rosen, Alan A.; Iseri, Oscar; Fishbein, Gary; Knodell, Robert G. // American Journal of Gastroenterology;Jan1991, Vol. 86 Issue 1, p86 

    Tender hepatomegaly and ascites occurred in a young woman receiving cytosine arabinoside and daunorubicin for acute myelogenous leukemia. Whereas venoocculusive disease was suspected clinically, liver biopsy showed nodular regenerative hyperplasia with no evidence of hepatic vein abnormalities....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics